Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials

References

• FitzGerald O, Ogdie A, Chandran V, et al. Psoriatic arthritis. Nat Rev Dis Primers. 2021;7(1):1. doi:10.1038/s41572-021-00293-y.
   PubMed Web of Science ®Google Scholar
• Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545–11. doi:10.1016/j.rdc.2015.07.001.
   PubMed Web of Science ®Google Scholar
• Kumthekar A, Ogdie A. Obesity and psoriatic arthritis: a narrative review. Rheumatol Ther. 2020;7(3):447–−456. doi:10.1007/s40744-020-00215-6.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Karki C, Liu M, et al. Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the corrona psoriatic arthritis/spondyloarthritis registry. RMD Open. 2018;4(1):e000638. doi:10.1136/rmdopen-2017-000638.
   PubMed Web of Science ®Google Scholar
• Coates LC, Soriano ER, Corp N, et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465–479. doi:10.1038/s41584-022-00798-0.
   PubMed Web of Science ®Google Scholar
• Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700.1–712. doi:10.1136/annrheumdis-2020-217163.
   Web of Science ®Google Scholar
• Singh JA, Guyatt G, Ogdie A, et al. 2018 American college of rheumatology/national psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res (Hoboken). 2019;71(1):2–29. doi:10.1002/acr.23789.
   PubMed Web of Science ®Google Scholar
• Skyrizi (risankizumab-rzaa) prescribing information. North Chicago (IL): AbbVie Inc.; 2024. [accessed 2024 April 10]. Available from https://www.rxabbvie.com/pdf/skyrizi_pi.pdf
   Google Scholar
• Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81(2):225–231. doi:10.1136/annrheumdis-2021-221019.
   PubMed Web of Science ®Google Scholar
• Östör A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2022;81(3):351–358. doi:10.1136/annrheumdis-2021-221048.
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatology (Oxford). 2022;62(6):2113–2121. doi:10.1093/rheumatology/keac607.
   Google Scholar
• Östör A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study. Rheumatology (Oxford). 2022;62(6):2122–2129. doi:10.1093/rheumatology/keac605.
   Google Scholar
• Felson DT, Anderson JJ, Boers M, et al. American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727–735. doi:10.1002/art.1780380602.
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum. 1998;41(9):1564–1570. doi:10.1002/1529-0131(199809)41:9%3C1564::AID-ART6%3E3.0.CO;2-M.
   PubMedGoogle Scholar
• Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. Acad Dermatol Venereol. 2015;29(4):645–648. doi:10.1111/jdv.12817.
   PubMed Web of Science ®Google Scholar
• Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(01):48–53. doi:10.1136/ard.2008.102053.
   PubMedGoogle Scholar
• Schoels MM, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811–818. doi:10.1136/annrheumdis-2015-207507.
   PubMed Web of Science ®Google Scholar
• Strand V, Boers M, Idzerda L, et al. It’s good to feel better but it’s better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol. 2011;38(8):1720–1727. doi:10.3899/jrheum.110392.
   PubMed Web of Science ®Google Scholar
• Leung YY, Ogdie A, Orbai AM, et al. Classification and outcome measures for psoriatic arthritis. Front Med. 2018;5:246. doi:10.3389/fmed.2018.00246.
   Web of Science ®Google Scholar
• Eder L, Thavaneswaran A, Chandran V, et al. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015;74(5):813–817. doi:10.1136/annrheumdis-2013-204448.
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi:10.1016/j.jaad.2018.11.057.
   PubMed Web of Science ®Google Scholar